NCT05132413

A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer

Status unknown Phase 3 Last updated 24 November 2021

What this trial tests

Phase 3 trial testing SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab in Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer in 561 participants. Status unknown.

Timeline

30 December 2021

Primary endpoint
30 December 2024

30 December 2024

Quick facts

Lead sponsor	Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	561
Start date	30 December 2021
Primary completion	30 December 2024
Estimated completion	30 December 2024

Drugs / interventions tested

• SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab — full drug profile →
• Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin — full drug profile →
• Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin — full drug profile →

Conditions studied

• Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer — all drugs for Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer →

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluate efficacy and safety of SHR-1701 in combination with bevacizumab and chemotherapy in advanced or metastatic non-squamous non-small-cell lung cancer with EGFR mutation after failure of TKIs

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. T cells in health and disease.
   Sun L, Su Y, Jiao A, Wang X, et al · · 2023 · cited 717× · PMID 37332039 · DOI 10.1038/s41392-023-01471-y
2. TGF-beta signal transduction: biology, function and therapy for diseases.
   Tie Y, Tang F, Peng D, Zhang Y, et al · · 2022 · cited 97× · PMID 36534225 · DOI 10.1186/s43556-022-00109-9
3. Development of therapeutic antibodies for the treatment of diseases.
   Wang Z, Wang G, Lu H, Li H, et al · · 2022 · cited 69× · PMID 36418786 · DOI 10.1186/s43556-022-00100-4
4. Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities.
   Yin N, Li X, Zhang X, Xue S, et al · · 2024 · cited 48× · PMID 38773064 · DOI 10.1038/s41392-024-01826-z
5. Targeting transforming growth factor beta signaling in metastatic osteosarcoma.
   Ge R, Huang GM. · · 2023 · cited 25× · PMID 38021074 · DOI 10.1016/j.jbo.2023.100513
6. Therapeutic targeting of VEGF and/or TGF-β to enhance anti-PD-(L)1 therapy: The evidence from clinical trials.
   Li L, Wen Q, Ding R. · · 2022 · cited 17× · PMID 35957885 · DOI 10.3389/fonc.2022.905520
7. Consensus on the lung cancer management after third-generation EGFR-TKI resistance.
   Zhou Q, Zhao H, Lu S, Cheng Y, et al · · 2024 · cited 14× · PMID 39759798 · DOI 10.1016/j.lanwpc.2024.101260
8. Bispecific antibodies: unleashing a new era in oncology treatment.
   Shui L, Wu D, Yang K, Sun C, et al · · 2025 · cited 6× · PMID 40760704 · DOI 10.1186/s12943-025-02390-y